维普期刊资源整合服务平台（V6.5）

198篇 您的检索式：作者名="DI LEO A"

选中清除导出查看参考文献查看引证文献引用追踪共10页首页上一页第1页下一页末页 /10 跳转

	题名	作者	年代	出处	被引量
1	HER-2 amplification and topoisomerase 11 alpha gene aberration as predictive markers in node - positive breast cancer patients randomly treated either withan anthracycline - based therapy or with eyclophosphamide, methotrexate, and 5 - fluorouracil显示文摘	Di Leo A Gabcberg D Larsimont D	2002	Clinical Cancer Res2002，8，：	1
2	Experience of endoscopic ultrasound in staging adenocarcinoma of the cardia显示文摘	De Manzoni G Pedrazzoni C Di Leo A	1999	Eur J Surg Oncol1999，25，：	1
3	Phase 11显示文摘	di LEO A GOMEZ HL AZIZ Z	2008	J Clin Oncol2008，26，34：	1
4	HER2:a predictive factor ready to use in the daily management of breast patients显示文摘	Piccorf MJ Di Leo A Hamilton A		0，，：	1
5	HER-2 and topoi- somerase llalpha as predictive cancer patients randomly treated with adjuvant CMF or epirubicin plus cyelophosphamide显示文摘	Di Leo A Larsimont D Gabcberg D	2001	Ann Oncol2001，12，：	1
6	A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol 显示文摘	Fasano T Cefalu A B Di Leo E	2007	Arterioscler Thromb Vasc Biol2007，27，3：	1
7	Chromogenic in situ hy-bridization : a practical alternative for fluorescence in situ hybridiza- tion to detect HER-2/neu oncogene amplification in archival breast cancer samples 显示文摘	Tanner M Gancberg D Di Leo A	2000	Am J Pathol2000，157，5：	1
8	Final overall surviv- al: fulvestrant 500rag vs 250rag in the randomized CONFIRM trial显示文摘	Di Leo A Jerusalem G Petruzelka L	2014	J Nati Cancer Inst2014，106，1：	1
9	Metastases to the paraaortic lymph nodes in adenocarcinoma of the cardia 显示文摘	De Manzoni G Pedrazzani C Di Leo A	2001	Eur J Surg2001，167，6：	1
10	Management of triple negative breast cancer显示文摘	Oakman C Viale G Di Leo A	2010	Breast2010，19，5：	1
11	Tumor necrosis factor alpha and apoptosisin Helicobacter pylori related progressive gastric damage:a possible mechanism of immune system involvement in epithelial turnover regulation显示文摘	Ierardi E Di Leo A Barone M	2003	Immunopharmacol Immunotoxicol2003，25，2：	1
12	HER2 ampli- fication and topoisomerase Ⅱ alpha gene aberrations as predictive markers in nodepositive breast cancer patients randomly treated ei- ther with an anthracycline - based therapy or with cyclophospha- mide, methotrexate, and 5 - fluorouracil 显示文摘	DI LEO A GANCBERG D LARSIMONT D	2002	Clin Cancer Res2002，8，5：	1
13	A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline- based adjuvant therapy显示文摘	Di Leo A Isola J Piene F	2008	Breast Cancer Res Treat2008，107，：	1
14	Current status of HER2 testing显示文摘	Di Leo A Dowsett M Horten B	2002	Oncology2002，63，：	1
15	Management of triple negative breast cancer显示文摘	Oakman C Viale G Di Leo A	2010	Breast2010，19，5：	1
16	Estrogens and colorectal cancer显示文摘	di Leo A Messa C Cavallini A	2001	Curr Drug Targets Immune Endocr Metabol Disord2001，1，1：	1
17	Chromogenic in situ hybridization:a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples显示文摘	Tanner M Gancberg D Di Leo A	2000	Am J Pathol2000，157，5：	1
18	Results of the CONFIRM phase Ⅲ trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer显示文摘	Di Leo A Jerusalem G Petruzelka L	2010	J Clin Oncol2010，28，30：	1
19	New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer显示文摘	Di Leo A Claudino W Colangiuli D	2007	Ann Oncol2007，1812，：	1
20	A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy显示文摘	Di Leo A Isola J Piette F	2009	Cancer Res2009，69，：	1

返回顶部每页显示：

共10页首页上一页第1页下一页末页 /10 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示